Skip to main content
. 2021 Oct 28;9(11):1249. doi: 10.3390/vaccines9111249

Figure 2.

Figure 2

Stability of (A) ChAdOx1 RVF (X48A) and (B) ChAdOxRabG (X48D) in liquid formulation. (A) Tabulated rates of infectivity loss (k = reduction in log10 (titre) per month calculated by linear regression using data shown in Figure 1A,B) for the two viruses at three temperatures; (B) the same data in the form of an Arrhenius plot; (C) infectivity of samples of the two viruses over a series of freeze–thaw cycles.